(Total Views: 655)
Posted On: 05/22/2025 3:13:29 AM
Post# of 154119
I believe an option for an ICI will be part of the protocol, and that was at least part of the reason why the trial has taken so long to initiate.
Max Lataillade wrote on LinkedIn:
Max Lataillade wrote on LinkedIn:
Quote:
... CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!
(18)
(0)
